Los puntos clave no están disponibles para este artículo en este momento.
We provide evidence of as-yet-unappreciated MSI in several types of cancer. These findings support an expanded role for clinical MSI testing across multiple cancer types as patients with MSI-positive tumors are predicted to benefit from novel immunotherapies in clinical trials.
Bonneville et al. (Tue,) studied this question.